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An important component of chronic neurodegenerative diseases is the generation of an innate inflammatory response within the CNS.
Microglial and astroglial cells play a key role in the development and maintenance of this inflammatory response, showing enhanced
proliferation and activation.We studied the time course and regulation ofmicroglial proliferation, using amousemodel of priondisease.
Our results show that the proliferation of resident microglial cells accounts for the expansion of the population during the development
of the disease. We identify the pathway regulated by the activation of CSF1R and the transcription factors PU.1 and C/EBP as the
molecular regulatorsof theproliferative response, correlatingwith the chronichumanneurodegenerative conditionsvariantCreutzfeldt-
Jakob disease and Alzheimer’s disease. We show that targeting the activity of CSF1R inhibits microglial proliferation and slows neuronal
damage and disease progression. Our results demonstrate that microglial proliferation is a major component in the evolution of chronic
neurodegeneration, with direct implications for understanding the contribution of the CNS innate immune response to disease progression.
Introduction
Determining the relative contribution of proliferation and acti-
vation of microglial cells is essential for understanding the out-
come of CNS pathologies (Jensen et al., 1994; Ponomarev et al.,
2005). Whether microglial cells are locally renewed or are gen-
erated from bone-marrow-derived progenitors (BMPs) is a
controversial issue. Several studies point to in situmicroglial pro-
liferation as the major mechanism regulating microglial turn-
over, with little or no contribution of circulating progenitors
(Lawson et al., 1992; Prinz and Mildner, 2011). Microglia can be
maintained and function independently of BMPs in health
(Ginhoux et al., 2010; Schulz et al., 2012) and in disease, as evi-
denced using experimental models of demyelination, neurode-
generation, or axotomy (Ajami et al., 2007; Mildner et al., 2007,
2011). Therefore, analyzing the degree ofmicroglial proliferation
under pathological conditions is critical for understanding
how the innate inflammatory response contributes to disease
onset and progression.
Prion disease experimentalmodels present proteinmisfolding
and progressive neuronal degeneration, common to several neu-
rodegenerative diseases (Ransohoff and Perry, 2009). In prion
disease, microglial activation and the cytokine profile are similar
to that observed in models of Alzheimer disease (AD), with low
levels of inflammatory cytokines but high levels of TGF and
PGE2 (Perry et al., 2002; Cunningham et al., 2003). Moreover,
microglia in prion disease are primed by the ongoing pathology,
with an enhanced responsiveness to systemic inflammation
(Perry et al., 2007). Previous studies in prion disease suggested
thatmicroglia arose fromBMPs, as evidenced by the use of bone-
marrow chimeras (Priller et al., 2006). Given recent evidence
reporting side effects of whole-body irradiation (Prinz and
Mildner, 2011), microglial proliferation during the progression
of prion disease needs to be evaluated.
Signals produced during chronic neurodegeneration are can-
didates to trigger microglial proliferation. Endogenous brain
growth factors, like macrophage colony-stimulating factor
(CSF1), promote microglial proliferation (Yamamoto et al.,
2010) through the CSF1 receptor (CSF1R) (Raivich et al., 1998).
CSF1 is also upregulated in microglia in a model of AD (Murphy
et al., 2000). Furthermore, a novel cytokine, interleukin-34
(IL34), also activates CSF1R, driving in vitroproliferation ofmac-
rophages andmicroglia (Wei et al., 2010;Mizuno et al., 2011) and
defining aspects of microglial development (Wang et al., 2012).
At the transcriptional level, the C/EBP-PU.1 pathway is a can-
didate for the regulation of microglial proliferation, regulating
the expression of CSF1R (Zhang et al., 1994). PU.1 regulates
macrophage biology and granulopoiesis, and is expressed in mi-
croglia (Walton et al., 2000), being upregulated after brain injury
(Ponomarev et al., 2011). C/EBP has been shown to activate the
transcription of PU.1 in monocytes, regulating their differentia-
tion (Cai et al., 2008) and proliferation (Celada et al., 1996)
through CSF1.
Thus, understanding the factors that regulate microglial pro-
liferation during chronic neurodegeneration has yet to be stud-
ied. We provide evidence for a key role of activation of the
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CSF1R-PU.1-C/EBP axis in the control of microglial prolifera-
tion during chronic neurodegeneration. Also, modulating this
pathway, we identify the contribution of microglial proliferation
to the progression of prion disease, opening a new window to
potentially beneficial therapeutic approaches.
Materials andMethods
Experimental models of prion disease
Female C57BL/6J (Harlan) and c-fms-EGFP (Sasmono et al., 2003)
(macgreen) mice were bred and maintained in local facilities. Mice ex-
pressing EGFP under the promoter of c-fms (CSF1R) are characterized
by the expression of green fluorescence in microglial cells. Mice were
housed in groups of 4–10, under a 12 h light/12 h dark cycle at 21°C, with
food and water ad libitum. To induce prion disease, mice were anesthe-
tized with a ketamine/rompun mixture (85 and 13 mg/kg), and 1 l of
either ME7-derived (ME7 animals) or 22L-derived (22L animals) brain
homogenate (10% w/v) or normal brain homogenate (NBH animals)
was injected stereotaxically and bilaterally at the coordinates from breg-
ma: anteroposterior,2.0 mm; lateral,1.7 mm; depth, 1.6 mm.When
required, mice received intraperitoneal BrdU (7.5 mg/ml, 0.1 ml/10 g
weight in sterile saline; Sigma-Aldrich) for the 4 d before the end of the
experiment. All procedures were performed in accordance with U.K.
Home Office licensing.
Clinical samples of variant Creutzfeldt–Jakob disease and AD
Human brain autopsy tissue samples (paraffin-embedded, formalin-
fixed, 96% formic acid-treated, 6 m sections) from the National CJD
Surveillance Unit Brain Bank (Edinburg, UK) were obtained from cases
of variant Creutzfeldt–Jakob disease (vCJD; 5 females and 5 males, age
20–34 years), AD (5 females and 5 males, age 58–76 years), or the cor-
responding age-matched controls (vCJD controls: 5 females and 5males,
age 20–35 years; AD controls: 4 females and 5males, age 58–79 years) in
whom consent for use of autopsy tissues for research had been obtained.
All cases fulfilled the criteria for the pathological diagnosis of vCJD or
AD.None of the cases had any of the knownmutations of the PrP gene or
family history of prion disease, and therewas no evidence of the common
types of iatrogenic etiology. Ethical permission for research on autopsy
materials stored in the National CJD Surveillance Unit was obtained
from Lothian Region Ethics Committee.
Gain/loss of activity of CSF1R
For loss of function experiments, NBH (control) and ME7 (prion)
macgreen mice were treated at 12 weeks postinjection with a CSFR1
blocking antibody (1 g; LEAF Purified anti-mouse CD115, n 4; Bio-
legend) (MacDonald et al., 2010) or an isotype control antibody (Rat
IgG; 1 g, n  4) by stereotactic injection in the dorsal hippocampus
(CA1 field; anteroposterior,2.0mm; lateral,1.7mm; depth, 1.6mm)
with a Hamilton syringe. Mice received five injections of intraperitoneal
BrdU (7.5 mg/ml, 0.1 ml/10 g weight in sterile saline) before the end of
the experiment (1 week).
Similarly, for gain of function experiments, NBH (control) and ME7
(prion) macgreenmice were treated at 12 weeks postinjection with 50 ng
of recombinant murine CSF1 (n  4; Merck Chemicals), murine IL34
(n 4; R&D Systems), or saline (vehicle; n 4) by stereotactic injection
in the dorsal hippocampus (CA1 field; anteroposterior, 2.0 mm; lat-
eral,1.7 mm; depth, 1.6 mm) with a Hamilton syringe. Mice received
five injections of intraperitoneal BrdU (7.5 mg/ml, 0.1 ml/10 g weight in
sterile saline) before the end of the experiment (1 week).
Inhibition of the tyrosine kinase activity of CSF1R was achieved by the
administration of GW2580, as previously described (Conway et al., 2005;
Crespo et al., 2011). GW2580 (LC Laboratories) was suspended in 0.5%
hydroxypropylmethylcellulose and 0.1% Tween 80 and was dosed orally
at 0.2 ml per mouse (75 mg/kg) daily for 4 consecutive weeks (from 14th
to 18th week postinjection) toME7mice (ME7GW2580; n 8) using
the vehicle as control (ME7  vehicle; n  8) and comparing to NBH
mice (n  8). Mice behavior and weight was monitored during the ex-
periment.Mice received two daily injections of intraperitoneal BrdU (7.5
mg/ml, 0.1 ml/10 g weight in sterile saline) before the end of the experi-
ment (18th week). A subgroup of mice was maintained to complete the
behavioral analysis and to study the effect of the treatments over the
survival time (terminal disease as assessed by a loss of 15% body weight).
Inhibition of proliferation by cytosine arabinoside
NBH (control) and ME7 (prion) mice were treated with 2% cytosine
arabinoside (AraC; n 4; Sigma-Aldrich), a dose previously used in the
literature and extensively reported to have no detrimental effects on
nondividing cells (Doetsch et al., 1999). We used sterile saline (n 4) as
vehicle, and the treatments were performed for 1 month (from 12th to
16th week postinfection), using an intraventricular brain infusion kit
(anteroposterior, 0.0 mm; lateral, 1.0 mm; Alzet) coupled to an os-
motic minipump (model 1004, flow 0.11l/h; Alzet). Mice received two
daily injections of intraperitoneal BrdU (7.5mg/ml, 0.1ml/10 gweight in
sterile saline) before the end of the experiment (16th week). The pump
weight, measured before and after the experiment, and the placement of
the intraventricular cannula were checked to ensure correct delivery of
the treatments.
Behavioral tests
From the eighth week postinjection, mice treated with ME7  vehicle
(n 8),ME7GW2580 (n 8), or NBH (n 8) were tested weekly on
behavioral tasks previously demonstrated to detect the onset of behav-
ioral dysfunction (Boche et al., 2006): open-field locomotor activity,
burrowing activity, motor performance on horizontal bar, and glucose
consumption.
Open-field locomotor activity. The open-field tests were performed us-
ing activity monitor software (Med Associated). Themice were placed in
individual cages of 27  27  0.3 cm for a period of 3 min to further
analyze the total distance traveled (cm) and the number of rears (vertical
counts), using the average speed as an internal control of the mouse
motor abilities, during the test period (3 min).
Burrowing. Plastic cylinders, 20 cm long and 6.8 cm in diameter, were
filled with 190 g of normal diet food pellets and placed in individual
mouse cages. Mice were placed individually in the cages for 2 h and
overnight, and the remaining pellets were weighed at the end of each
session and the amount displaced (“burrowed”)was calculated. Themice
were then returned to their home cage.
Glucose consumption. Glucose consumption for individual mice was
measured at the same time as the burrowing. The water bottles were
removed and refilled with a 5% glucose solution (d()-glucose; BDH
Laboratory Supplies) and weighed. The following morning, the bottles
were reweighed, and the amount drunk was calculated.
Horizontal bar motor test. The test was performed in a 38-cm-long
metal bar with a diameter of 0.2 cm that was supported by wooden struts
to a height of 49 cm over a padded bench surface. Mice were held by the
tail and allowed to grip the center of the bar with their front paws only.
The tail was rapidly released and time taken to fall off (60 s) or to reach
one of the wooden supports (contact with forepaw; max. 60 s) was
recorded.
Body weight and late-stage clinical signs of disease. Body weights of all
mice were monitored on a weekly basis from 8 weeks postinjection.
Terminal disease was defined as a humane end-point of a loss of15%
bodyweight and/or the development of severe clinical signs; at this point,
animals were killed.
Immunohistochemistry
Coronal hippocampal sections were cut from formalin-fixed, paraffin-
embedded, or paraformaldehyde-fixed frozen brains. Mice perfusion,
tissue processing, and immunohistochemical analysis were performed as
previously described (Go´mez-Nicola et al., 2008). After processing the
paraffin-embedded sections for dewaxing and antigen retrieval (citrate
buffer, 5 min boil, 3 min stand, 5 min boil) the sections were treated
successively with 1% methanol/30%H2O2 and 5% normal serum/0.1%
BSA to block endogenous peroxidase and nonspecific binding, re-
spectively. After repeated rinses with PBS  Tween 20 (PBST; 0.1%
v/v), they were incubated overnight at 4°C with the correspondent
primary antibodies: goat anti-Iba1 (Abcam), rat anti-CD11b (AbD
Serotec), chicken anti-GFP (Abcam), mouse anti-GFAP (Millipore),
mouse anti-NeuN (Millipore), mouse anti-BrdU (Developmental Stud-
ies Hybridoma Bank), rat anti-BrdU (Santa Cruz Biotechnology), rabbit
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anti-proliferating cell nuclear antigen (anti-PCNA; Abcam), rabbit anti-
phospho-histone H3 (Cell Signaling Technology), rabbit anti-Ki67 (Ab-
cam), goat anti-IL34 (Santa Cruz Biotechnology), goat anti-C/EBPa
(Santa Cruz Biotechnology), rabbit anti-PU.1 (Santa Cruz Biotechnol-
ogy), hamster anti-CD11c (in house), rat anti-MHCII (eBioscience),
rabbit anti-IL1b (Peprotech), and rabbit anti-cleaved caspase-3 (Milli-
pore). Following primary antibody incubation, the sections were washed
with PBST and incubated with the appropriate biotinylated secondary
antibody (Vector Labs), and/or with the appropriate Alexa 405-, 488-, or
594-conjugated secondary antibody or streptavidin (Invitrogen). For
light microscopy, the sections were washed and incubated with Vec-
tastain ABC complex (Vector Labs) and visualized using diamino-
benzidine (DAB) precipitation. Sections for light microscopy were
counterstained with hematoxylin and mounted with DePeX and visual-
ized in Leica CTR 5000 microscope, coupled to a Leica DFC300FX mi-
croscope camera. After immunofluorescence labeling, nuclei were
visualized by Hoechst staining and the sections were mounted with
Mowiol/DABCO (Sigma-Aldrich) mixture. The sections were visualized
on a Leica TCS-SP5 confocal system, coupled to a Leica CTR6500
microscope.
The general immunohistochemistry protocol was modified for the
detection of BrdU, as previously described (Go´mez-Nicola et al., 2011).
Briefly, sectionswere subjected to antigen retrieval with citrate buffer and
DNA denaturation with 2N HCl (30 min, 37°C), followed by blocking
and incubation of the primary and secondary antibodies for the general
protocol. Detection of BrdU in macgreen mice sections was combined
with the antibody-based detection of EGFP to recover the loss of fluores-
cence generated by the BrdU detection protocol.
Detection of the PrPSc proteinwas performed following the previously
described protocol (citrate buffer  2N HCl) using a mouse anti-PrP
primary antibody [mouse anti-PrP (Prionics)] and detecting the signal
with DAB.
The protocol used for immunohistochemistry on human sections was
a modification of the general protocol, with antigen unveiling in citrate
buffer being performed for 25 min. When fluorescent detection was
performed, an additional incubation in 0.1% Sudan Black in 70% EtOH
for 10 min was added to reduce autofluorescence just before the incuba-
tion with the secondary fluorescently labeled antibodies.
Detection of neuronal degeneration was performed using the staining
with Fluoro Jade C (Merck Millipore), according to the manufacturer
instructions. Briefly, sections were incubated in 0.06% potassium per-
manganate for 10 min, followed by two washes in H2O. Then, sections
were incubated for 10 min in a solution of 0.0001% Fluoro Jade C dye
dissolved in 0.1% acetic acid, followed by washing in H2O, drying, clear-
ing with xylene, and mounting with DePeX.
Quantification and image analysis
The quantification of antigen-positive cells (i.e., Iba1) in the specific
areas (n  4 fields/mouse, n  4–8 mice/group) was performed after
DAB immunohistochemistry. The number of double-positive cells (i.e.,
GFPBrdU) in the specific area (n  4 fields/mouse, n  4–8 mice/
group) was performed after double immunofluorescence. Data were
represented as number of positive cells per square millimeter. Quantifi-
cation of the number of PrPSc plaques was performed after PrP-specific
immunohistochemistry in the CA1 layer of the hippocampus (plaques/
mm2; n  4 fields/mouse, n  4 mice/group). The quantification of
antigen-positive cells (i.e., IL34) in human brains was performed in the
white or gray matter of the temporal cortex after DAB immunohisto-
chemistry (n 10 fields/brain, n 9–10 brains/group). The quantifica-
tion of Fluoro JadeC-positive neuronswas performed in theCA1 layer of
the hippocampus (neurons/section; n 4 sections/mouse, n 4 mice/
group). All quantifications were performed with the help of the ImageJ
image analysis software.
Analysis of gene expression by RT-PCR
NBHorME7 fresh frozen brain sectionswere cutwith a cryostat, then the
CA1 area of the hippocampus and the dorsal thalamic region were dis-
sected under a dissecting microscope. Alternatively, samples of the hip-
pocampus or the thalamus were obtained from fresh brains (experiment
GW2580) by dissection under a microscope. Samples were homoge-
nized in Trizol reagent (Invitrogen), following the manufacturer in-
structions to isolate RNA, as previously described (Go´mez-Nicola et
al., 2011). The isolated RNA was quantified (Nanodrop; Thermo Sci-
entific) and retrotranscribed to cDNAwith a RT Precision Nanoscript
kit (Primer-Design) after checking its integrity by electrophoresis in a
2% agarose gel. cDNA libraries were analyzed by RT-PCR using the
Precision 2X qPCR Mastermix (Primer-Design) and the custom de-
signed gene-specific primers (Sigma-Aldrich): csf1 [NM_007778.4;
forward (FW), agtattgccaaggaggtgtcag; reverse (RV), atctggcat-
gaagtctccattt), il34 (NM_001135100.1; FW, ctttgggaaacgagaatttggaga;
RV, gcaatcctgtagttgatggggaag), Csf1r (NM_001037859.2; FW, gcag-
taccaccatccacttgta; RV, gtgagacactgtccttcagtgc), pu.1 (NM_011355.1;
FW, cagaagggcaaccgcaagaa; RV, gccgctgaactggtaggtga), c/ebpa (NM_
007678.3; FW, agcttacaacaggccaggtttc; RV, cggctggcgacatacagtac),
gata1 (NM_008089.1, FW, tcagcaaacgggcaggcacc; RV, ctccgctggcattc-
ctccgc), cyclin D1 (NM_007631.2; FW, ggctcctctcatggcgctgc; RV,
gtggcatgcacaacaggccg), cyclin D2 (NM_009829; FW, tcgatgggctgcgtt-
gcgtt; RV, gggagcctgcgtcaaagggg), il1b (NM_008361.3; FW, cagac-
ccaccctgca; RV, accgtttttccatcttcttct), il6 (NM_031168.1; FW,
tccagaaaccgctatgaagttc; RV, caccagcatcagtcccaaga),mhcII (NM_010378.2; FW,
agctctgattctgggggtcctcg; RV, ataaacgccgtctgtgactgact), arg1 (NM_007482.3;
FW, agcactgaggaaagctggtc; RV, cagaccgtgggttcttcaca), and ym1 (NM_009892;
FW, agctctccagaagcaatcct; RV, ctgtccttagcccaactggt). The amplification
of DNAwas detected by SYBR green fluorescence. Quality of the primers
and the PCR were evaluated by electrophoresis in a 1.5% agarose gel,
checking the PCR product size. Data were analyzed using the Ct
method with Primer Opticon 3 software, usingGAPDH (NM_008084.2;
FW, tgaacgggaagctcactgg, RV, tccaccaccctgttgctgta) as a housekeeping
gene.
Statistical analysis
Data were expressed as mean  SEM and analyzed with the Prism 5
software package (GraphPad Software). For all datasets, normality and
homoscedasticity assumptions were reached, validating the application
of the one- or two-way ANOVA, followed by the Tukey post hoc test for
multiple comparisons. Survival curves were analyzed with Mantel–Cox
test for Kaplan–Meir curves. PrPSc and Fluoro Jade C stainings were
analyzed with a two-tailed t test. Differences were considered significant
for p 0.05.
Results
Time course of microglial proliferation during prion disease
The pathological course of prion disease is characterized by a
progressive expansion of the microglial population (Iba1 cells;
Fig. 1A) when compared with the control (NBH). Increased mi-
croglial density is present but varies across different regions such
as the hippocampus (CA1) and the thalamus (TH), the later
showing the biggest increase in cell numbers (Fig. 1A). In con-
trast, the number of astrocytes (GFAP cells) remains un-
changed in CA1 until the late stage of the disease (20 weeks), with
the thalamus showing an early expansion of the astrocytic popu-
lation (Fig. 1B). These changes are also present in another model
ofmurine prion disease, the 22Lmodel, withminor differences in
the overall cells numbers betweenME7 and 22Lmodels (Table 1).
The analysis of the expression of PCNA and phospho-
histone-H3 (pHH3), markers of proliferating cells, showed a
significant increase in the number of proliferating cells in prion-
diseased mice compared with the NBH controls (Fig. 1C,D). The
increase in proliferation is also observed in the 22L model of
prion disease (Table 1).
Moreover, the analysis of the incorporation of BrdU inmicro-
glial cells (GFP) showed an increased proliferative activity of
themicroglial population from early stages of prion disease com-
pared with the NBH controls (Fig. 1E). The regional and tempo-
ral distribution of BrdUmicroglial cells (Fig. 1E) correlates well
with that observed for the proliferativemarkers PCNAandpHH3
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(Fig. 1C,D) and the microglial marker Iba1 (Fig. 1A), supporting
the idea of the expansion of themicroglial population as themain
cell type proliferating during prion disease. This idea is supported
by the fact that the BrdU/GFP population (proliferating non-
microglial cells) represents amaximumof 5.2 1.3% of the total
BrDU positive cells (ME7, 20 weeks).
These results show a time-dependent resident microglial pro-
liferative response during the course of prion disease, generating
the expansion of the cell population.
Signals regulating microglial proliferation during
prion disease
Once local proliferation was established as the main driving
force responsible for expanding the microglial population
during prion disease (Fig. 1), we analyzed the expression and
localization of the components of the CSF1R signaling path-
way (Fig. 2). The mRNA expression of CSF1R and CSF1 is
progressively increased during prion disease compared with
the NBH controls (Fig. 2A). In contrast, the mRNA expression
Figure 1. Temporal and regional distribution of microglial proliferation during prion disease. A, B, Immunohistochemical analysis of the expression of Iba1 (microglia, A) and GFAP (astrocytes,
B) in the CA1 region of the hippocampus (see representative images) and the thalamus of prion-diseased (ME7) and control (NBH) mice. Quantified data expressed as mean SEM of the number
of Iba1 (A) or GFAP (B) cells per square millimeter. C, D, Immunohistochemical analysis of the expression of PCNA (A) and pHH3 (B) in the CA1 region of the hippocampus (see representative
images) and the thalamus of prion disease (ME7) and control (NBH)mice. Quantified data expressed as themean SEM of the number of PCNA (A) or pHH3 (B) cells per squaremillimeter. E,
Analysis of proliferative microglia (white arrowheads) by double immunofluorescence for BrDU (red) and GFP (microglia, green) in the hippocampus (CA1; representative image) and thalamus of
prion (ME7) or control (NBH)mice. Quantifieddata expressedasmean SEMof thenumber of BrDUGFP cells per squaremillimeter. *p0.05, **p0.01, ***p0.001.Datawere analyzed
with a two-way ANOVA and a post hoc Tukey test (n 6). A–D, Nuclei are stained with H/E (blue). E, Fluorescent sections evaluated with confocal microscopy. Scale bars: A–D (in A, C), 100m;
A–D, insets (in A, C) 50m; E, 20m.
Table 1. Expression of markers of glial cells and proliferation in the 22L and theME7models of prion disease
NBH ME7 22L
CA1 TH CA1 TH CA1 TH
Iba1 63.31 12.43 64.57 9.39 240.66 22.13*** 328.15 34.94*** 228.30 22.63** 282.71 14.31**
GFAP 387.94 21.03 19.21 4.64 409.45 22.44 448.31 26.58*** 362.81 55.37 529.76 26.50***
PCNA 13.04 1.06 18.30 5.61 83.54 13.66* 126.96 29.07* 41.21 3.26* 164.94 36.44**
pHH3 3.08 0.51 1.70 0.40 16.23 2.36** 17.74 3.66* 14.70 3.12* 13.93 1.57*
Immunohistochemical analysis of the expression of Iba1 (microglia), GFAP (astrocytes), PCNA (proliferation), and pHH3 (proliferation) in the CA1 region of the hippocampus and the thalamus of prion disease (ME7, 22L) and control (NBH)
mice. Quantification data expressed as mean SEM of the number of positive cells per square millimeter. *p 0.05, **p 0.01, ***p 0.001. Data were analyzed with a two-way ANOVA and a post hoc Tukey test.
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of IL34, an alternative ligand for CSF1R, is upregulated in
prion mice at 12 weeks after inoculation, but returns to basal
levels at 20 weeks (Fig. 2A). The time course of the mRNA
expression of IL34 correlated with the protein expression, as
evidenced by its detection by immunohistochemistry (Fig.
2B,C). IL34 was found to be expressed in GFAP astrocytes,
in close contact with GFP/IL34-negative microglial cells
(Fig. 2D). IL34 staining was abolished by preincubation of the
antibody with IL34 peptide.
The observed time course of the expansion of the microglial
population (Fig. 1) correlated with the expression of the tran-
scription factor PU.1, which is upregulated during the develop-
ment of the prion disease at the mRNA level (Fig. 2E) and
detected by immunohistochemistry (Fig. 2F,G). The increase of
PU.1 cells was comparable in the different regions analyzed
(CA1 andTH, Fig. 2F,G; CA3, corpus callosum, data not shown),
with some minor differences in the overall number of positive
cells. The transcription factor C/EBP was also upregulated dur-
Figure 2. Temporal and regional distribution of the regulators ofmicroglial proliferation during prion disease.A, Analysis of the expression ofmRNA of CSF1, IL34, and CSF1R in the hippocampus
(CA1) and thalamus of prion disease (ME7) and control (NBH) mice. Expression of CSF1, IL34, and CSF1R is represented as mean SEM and indicated as relative expression levels using the 2Ct
method.B, C,F–H, Immunohistochemical analysis of the expression of IL34 (B, C), PU.1 (F,G), and C/EBPa (F,H ) in the CA1 region of the hippocampus (see representative images) and the thalamus
of prion disease (ME7) and control (NBH) mice. Quantified data expressed as mean SEM of the number of IL34, PU.1, or C/EBP cells per square millimeter. D, Analysis of the
expression of IL34 in glial cells by triple immunofluorescence for IL34 (red), GFP (microglia, green), and GFAP (astrocytes, blue) in the hippocampus (CA1) of prion disease mice (ME7).
E, Analysis of the expression of mRNA of PU.1, GATA1, and C/EBPa in the hippocampus (CA1) and thalamus of prion disease (ME7) and control (NBH) mice. Expression of PU.1, GATA1, and
C/EBPa is represented as mean SEM and indicated as relative expression levels using the 2Ct method. I, Analysis of the expression of PU.1 or C/EBPa (red) in microglial cells (GFP,
green) by double immunofluorescence in the hippocampus (CA1) of prion disease mice (ME7). *p 0.05, **p 0.01, ***p 0.001, ****p 0.0001. Data were analyzed with a
two-way ANOVA and a post hoc Tukey test (n 6). C, G, H, Nuclei are stained with H/E (blue). I, Nuclei are stained with Hoechst (blue). D, I, Fluorescent sections evaluated with confocal
microscopy. Scale bars: C, G, H, 100m; insets, 50m; D, I, 50m.
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ing the course of the priondisease at themRNA level (Fig. 2E) and
detected by immunohistochemistry (Fig. 2F,H). The expression
of C/EBP was similar in CA1 and TH (Fig. 2E,F,H), appearing
unchanged in other regions analyzed, like corpus callosum (data
not shown). Both PU.1 and C/EBP are expressed in GFPmi-
croglial cells in prion-diseased brains, as evidenced by confocal
microscopy (Fig. 2I). The expression of GATA1, a known nega-
tive regulator of PU.1 (Zhang et al., 1999), in prion-diseased
brains was not significantly different from that observed in NBH
controls (Fig. 2E).
Altogether, these results point to the signaling through the
CSF1R and the activation of PU.1 and C/EBP as the mitogenic
pathways driving the proliferation of microglial cells during
chronic neurodegeneration.
Signaling through CSF1R controls microglial proliferation
The temporal and regional expression of CSF1, IL34, and CSF1R
during prion disease highlighted the potential importance of this
system in regulating microglial proliferation. Thus, we analyzed
the function of these molecules using gain and loss of activity
experiments (Fig. 3).
To investigate the relevance of CSF1R in controlling micro-
glial proliferation, we inhibited its activity by the intrahippocam-
pal administration of a blocking antibody (CSF1R Ab), followed
by sequential administration of BrDU (Fig. 3), using a control
isotype-matched antibody as an internal control. The CSF1R Ab
efficiently binds to GFPmicroglial cells, as detected by immu-
nohistochemistry (Fig. 3A). Moreover, high levels of antibody
binding to the microglial cell inversely correlated with the levels
of expression of GFP, highlighting the effective inhibitory activity
over the CSF1R activation (Fig. 3A). The administration of
CSF1R Ab blocked microglial proliferation in the hippocampus
in both ME7 mice and in NBH controls, as evidenced by the
reduced levels of incorporation of BrDU in microglial cells
(GFP) compared with the hippocampi injected with a control
antibody (Fig. 3B). Blocking the CSF1R reduced the expansion of
the microglial population in prion mice without affecting their
morphological activation status (Fig. 3B). The administration of
the CSF1R blocking antibody did not cause a significant increase
in the apoptosis (cleaved-caspase-3) ofmicroglial cells (GFP)
(Fig. 3C). We found that caspase-3/GFP microglia repre-
sented 2.4 0.6% of the population in ME7 hippocampi treated
withCSF1R blocking antibody, not differing from the 1.8 0.5%
found in hippocampi treated with the control antibody. This
indicates that a change in proliferation alone, as a consequence of
blocking CSFR1, is sufficient to account for the change in density
of GFPmicroglia.
We studied the mitogenic activity of CSF1 and IL34 in prion-
diseased mice (Fig. 3D). We administered 50 ng of CSF1, IL34 or
vehicle [saline (SAL)] into the hippocampi of prion-diseased
mice, followed by the sequential administration of BrDU (Fig.
3D). The basal degree of proliferation (SAL) was increased by
the administration of either CSF1 or IL34, with a greater promi-
togenic effect of the latter (Fig. 3D). We found a significantly
higher number of proliferating microglial cells (BrDUGFP),
and total microglial cells (GFP) in the hippocampi of prion
mice administered with CSF1 or IL34 compared with the saline
controls (Fig. 3D).
These experiments support the prominent role of signaling
through CSF1R by CSF1 or IL34 as the main driver of microglial
proliferation during the course of prion disease.
The inhibition of microglial mitosis alters the inflammatory
activation state
Given the proliferative potential of the resident microglial cells,
we investigated the relevance of microglial proliferation for the
progression of the disease by using a sustained intracranial deliv-
ery of AraC as an antimitotic agent (Fig. 4).
The intracerebral administration of AraC with mini-osmotic
pumps caused a significant decrease in cell proliferation in prion-
diseased mice compared with saline-treated mice or NBH con-
trols, evidenced by the reduced incorporation of BrDU (Fig. 4A).
In parallel, the total number ofmicroglial cells (GFP) decreased
upon treatment with AraC, stopping the expansion observed in
saline-treated ME7 mice and keeping the population at control
levels (Fig. 4A). We observed a homogeneous effect of the AraC
across different regions, such as the hippocampus and the thala-
mus (Fig. 4A). A conspicuous side effect of the inhibition of
microglial mitosis with AraC was a shift in the phenotypic acti-
vation of the microglia of prion mice, with an increase in the cell
body size and thickness of the processes (Fig. 4D). Moreover, as a
result of the AraC treatment, microglial cells (GFP) in prion
mice increased the expression of CD11c, MHCII, and IL1 com-
pared with saline-treated mice (Fig. 4B). Also, at the single-cell
level, we observed an inverse correlation of the expression of the
CSF1R (GFP) with the expression of CD11c, a marker associ-
ated with antigen-presenting cells (Fig. 4C). As a consequence of
the development of a proinflammatory phenotype, blocking of
microglial proliferation with AraC had a detrimental neuro-
pathological effect (Fig. 4E). Although the misfolding and depo-
sition of PrPsc was not affected (Fig. 4E, left), AraC caused
increased neurodegeneration inME7mice, as evidenced by stain-
ingwith Fluoro JadeC inCA1 (Fig. 4E).We found no Fluoro Jade
C cells in AraC-treated NBH controls, evidencing the lack of
toxicity of the treatment at this concentration (data not shown).
Together, these results suggest that a general inhibition ofmitosis
in the presence of the major mitogens CSF1 and IL34 has a dra-
matic impact on the phenotype of microglial cells, shifting them
to an M1-like antigen-presenting phenotype and accelerating
neuronal degeneration.
The selective inhibition of CSF1R activity blocks microglial
proliferation and delays the pathological course of prion
disease
Based on the observed dependence on CSF1R of microglial pro-
liferation, we evaluated the activity of GW2580, a selective inhib-
itor of the CSF1R tyrosine kinase activity (Conway et al., 2005;
Crespo et al., 2011) to identify the specific contribution of the
expansion of the microglial population to the progression of the
disease.
The administration of GW2580 caused a significant reduction
in microglial proliferation in prion-diseased mice, revealed by a
decrease in the number of CD11b and BrDU cells in the
hippocampus, compared with the effect of the vehicle (Fig. 5A).
We also found a downregulation of the microglial mitogenic ef-
fectors CSF1R, PU.1, and C/EBP in response to treatment with
GW2580 in ME7 mice, associated with a decreased expression of
the CSF1R downstream regulators of the cell cycle (Yamamoto et
al., 2012), cyclins D1 andD2 (Fig. 5B). GW2580 caused the reduc-
tion of the expression of IL1 and IL6, cytokines characteristic of
the M1 inflammatory phenotype, and the marker of antigen pre-
sentation MHCII (Fig. 5C), opposing the previously observed
adverse effects of the inhibition of mitosis with AraC (Fig. 4).
Complementarily, GW2580 increased the expression of ARG1
and YM1, markers characteristic of an M2 inflammatory pheno-
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Figure3. Signaling through theCSF1R controlsmicroglial proliferationduring chronic neurodegeneration.A,B, Effect of the administrationof a CSF1Rblocking antibody (CSF1RAb) onmicroglial
proliferation (A, right). A, Immunofluorescent analysis of the binding of CSF1R Ab (red) to microglial cells (GFP, green), expressing low (white arrowheads) or high (empty arrowheads) levels of
CSF1R (GFP) in the hippocampus of prion diseasemice (ME7).B, Analysis of microglial proliferation by double immunofluorescence for BrDU (red) and GFP (microglia, green) in the hippocampus of
prion (ME7, representative images) or control (NBH) mice treated with CSF1R Ab or an isotype control antibody (CTL). Quantified data expressed as mean SEM of the number of BrDUGFP
(proliferative microglia) or GFP (total microglia) cells per square millimeter. C, Immunofluorescent analysis of the expression of activated (cleaved) caspase-3 (red) in microglial cells (GFP,
green,white arrowheads) or nonmicroglial cells (empty arrowheads) in thehippocampusof priondiseasemice (ME7).D, Effect of the administrationof CSF1or IL34onmicroglial proliferationduring
prion disease (C, right). Analysis ofmicroglial proliferation by double immunofluorescence for BrDU (red) andGFP (microglia, green) in the hippocampus of prion (ME7)mice treatedwith CSF1, IL34,
or saline (control, Sal). Quantified data expressed asmean SEM of the number of BrDUGFP (proliferativemicroglia) or GFP (totalmicroglia) cells per squaremillimeter. *p 0.05, **p
0.01, ***p 0.001. Data were analyzed with a one- (B) or two-way (D) ANOVA and a post hoc Tukey test (n 4). A–D, Fluorescent sections evaluated with confocal microscopy. Scale bars: A, 20
m; B–D, 50m.
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Figure 4. Blockade of mitosis alters the inflammatory phenotype of microglial cells during chronic neurodegeneration. A–E, Effect of the administration of an inhibitor of mitosis (AraC) on the
progressionofmicroglial proliferation andneuropathologyduringpriondisease (top).A, Analysis ofmicroglial proliferationby immunohistochemistry forBrDUandGFP(microglia,green, representative
images) in the hippocampus and thalamus of prion (ME7, representative images) or control (NBH) mice, treated with AraC or vehicle (saline, Sal), compared with naive mice. Quantified data
expressed as mean SEM of the number of BrDU or GFP cells per square millimeter. B, Effect of AraC on the expression of inflammatory markers in microglial cells, analyzed by double
immunofluorescence for CD11c, MHCII, or IL1b (red), and GFP (green, microglia), on the hippocampus of prion (ME7) or control (NBH) mice. Quantified data expressed as mean SEM of the ratio of
CD11c, MHCII or IL1b versus the total number of GFP microglial cells. C, Correlation of the expression of CD11c and GFP (CSF1R) in single microglial (Figure legend continues.)
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type (Fig. 5C). Also, blocking microglial proliferation in prion
disease had beneficial effects over the progression of the neuro-
pathology, evidenced as a decreased number of degenerating
neurons (Fluoro Jade C) in the hippocampus (CA1) upon
treatment with GW2580 (Fig. 5D). These results were compara-
ble to those found in the thalamus, where decreased microglial
proliferation was also observed, accompanied by a decreased ex-
pression ofCSF1R, PU.1,C/EBP, cyclin D1, cyclin D2, IL1, IL6,
and MHCII; and an increased expression of ARG1 and YM1 in
response to GW2580 (data not shown).
Treatment with GW2580 arrested the normal decay in bur-
rowing behavior observed from the 14th week in prion mice,
maintaining the levels close to those observed inNBH controls (2
and 24 h; Fig. 6A). Similarly, treatment with GW2580 prevented
the decay in glucose consumption observed in vehicle-treated
prion mice (Fig. 6B). Treatment with GW2580 also delayed the
loss of strength and motor coordination observed in vehicle-
treated prionmice, as observed by the performance on horizontal
bar (Fig. 6C). Similarly, the behavioral course of prion disease is
characterized by a phase of hyperactivity, observed in vehicle-
treatedmice and identified by an increase in the distance traveled
4
(Figure legend continued.) cells in the hippocampus of prion diseasemice, measured as relative
intensity.D, Effect of AraC or saline (vehicle) on themorphology of GFPmicroglial cells of the
hippocampus of prion (ME7) or control (NBH) mice. E, Effect of AraC or saline (vehicle) on the
deposition of PrP Sc (PrP Sc plaques, left) and the degeneration of neurons (Fluoro Jade
C-positive neurons, green, representative images, right) in the CA1 layer of the hippocampus of
prionmice (ME7). Quantified data expressed asmean SEMof number of PrP Scplaques per
square millimeter or Fluoro Jade C neurons in CA1. *p 0.05, **p 0.01, ***p 0.001.
Datawereanalyzedwithatwo-wayANOVAandaposthocTukeytest (n4).A,B,Nucleiarestained
withHoechst (blue).A–C, Fluorescent sectionsevaluatedwithconfocalmicroscopy.D, 2Dprojections
of 3D stacks under confocalmicroscopy. Scale bars:A, 200m;B, E, 20m;D, 10m.
Figure 5. Effect of the inhibition of CSF1R onmicroglial proliferation, inflammatory activation, and neuronal degeneration during prion disease. Effect of the inhibition of the signaling of CSF1R
by GW2580 onmicroglial proliferation (A, B), inflammatory activation (C), and neuropathology (D) of prion diseasemice (ME7GW2580) compared with control (NBH) or prionmice treated with
vehicle (ME7vehicle).A, Analysis ofmicroglial proliferationby immunohistochemistry for CD11b (microglia, red, representative images) andBrDU in thehippocampusofpriondisease treatedwith
GW2580 (ME7GW2580) or vehicle (ME7Vehicle) and control (NBH) mice. Quantified data expressed as meanSEM of the number of CD11b or BrDU cells/mm2. B, C, Analysis of the
expression of mRNA of CSF1R, PU.1, C/EBPa, cyclin D1, and cyclin D2 (B) and IL1b, IL6, MHCII, ARG1, and YM1 (C) in the hippocampus (CA1) of prion disease treated with GW2580 (ME7GW2580)
or vehicle (ME7Vehicle) and control (NBH) mice. B, C, mRNA expression is represented as mean SEM and indicated as relative expression levels using the 2Ct method. D, Effect of GW2580
or vehicle on the degeneration of neurons (Fluoro Jade C-positive neurons, green) in the CA1 layer of the hippocampus of prion (ME7) or control (NBH) mice. Quantified data expressed as mean
SEM of number of Fluoro Jade C neurons in CA1. *p 0.05, **p 0.01, ***p 0.001. Data were analyzed with a one-way ANOVA and a post hoc Tukey test (B, C) or a two-tailed t test (A, D),
n 4. Scale bars: 20m.
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and a decrease in the rears in the open
field (Fig. 6D). Treatment with GW2580
prevented prion mice from developing the
hyperactive behavioral deficit (Fig. 6D). In
linewith the delay of onset of the behavioral
deficits, treatment with GW2580 caused a
significant extension of the survival of
prion-diseased mice an average of 26.5 d
(Fig. 6E).
These results show a clear beneficial ef-
fect of GW2580 in slowing the progres-
sion of the chronic neurodegeneration,
highlighting the detrimental contribution
of microglial cells to the progression of
prion disease.
Themicroglial proliferation regulatory
system is active in human vCJD and AD
The experimentalmodels ofmurine prion
disease provided significant insights
about the dynamics and regulation of
microglial proliferation during chronic
neurodegeneration.However, wewere in-
terested to learn whether the system we
have described is active in other neurode-
generative conditions; we thus analyzed
the regional expression of the main com-
ponents of the pathway in brain samples
of patients of vCJD and AD.
The expression of IL34 is significantly
upregulated in the white matter in both
vCJD and AD brains compared with
the corresponding age-matched controls
(Fig. 7A,D). Although we found in-
creased numbers of IL34 cells in the gray
matter of vCJD and AD brains, this differ-
ence was not statistically significant in a
two-way ANOVA test (Fig. 7D). IL34 was
shown to be expressed in GFAP reactive
astrocytes of vCJD or AD brains, as evi-
denced by confocalmicroscopy (Fig. 7H).
The expression of PU.1 and C/EBP was
found to be significantly upregulated in
vCJD and AD brains, both in the white
and gray matter, compared with the cor-
responding age-matched controls (Fig.
7B,C,E,F).Moreover, we found evidence
ofmicroglial proliferation in the temporal
cortex of vCJD or ADbrains, as shown the
colocalization of Ki67 (marker of prolifer-
ation) in Iba1 cells (microglia; Fig. 7G).
We found no statistically significant dif-
ferences in the levels of IL34, PU.1, or
C/EBP between the vCJD and AD brains
that were analyzed.
Together, these results highlight the signaling through CSF1R
and the activation of the transcription factors PU.1 and C/EBP in
twodifferent conditions of humanneurodegeneration, vCJDandAD.
Discussion
The results reported here represent the first evidence of the reg-
ulation of microglial proliferation during the progression of
chronic neurodegeneration.We show that the residentmicroglial
population is expanded during the pathological course of prion
disease and that they contribute to disease progression.
The expansion of the microglial population is a hallmark of the
progression of diverse neuropathologies.Here,we show that there is
a dramatic increase in the number of microglial cells during the
development of prion disease. Our results are in line with previ-
ous studies supporting the hypothesis of local proliferation of
Figure 6. Effect of the inhibition of microglial proliferation over the progression of prion disease. Effect of the inhibition of the
signaling of CSF1R by GW2580 on the behavioral performance (A–D) and survival (E) of prion disease mice (ME7GW2580)
compared with control (NBH) or prion mice treated with vehicle (ME7vehicle). A, Effect of the different treatments on the
burrowing behavior, measured as weight displaced (in grams) off the tube in 2 or 24 h.B, Effect of the different treatments on the
glucose consumption, measured as weight consumed (in grams) of 5% glucose in water. C, Effect of the different treatments on
themotor performance,measured as time spent (in seconds) on the horizontal bar test.D, Effect of the different treatments on the
locomotor activity, measured as distance traveled (cm) and number of rears (vertical counts) in the open field test. E, Effect of the
different treatments on the survival, analyzed in a Kaplan–Meier curve. *p 0.05, **p 0.01, ***p 0.001, ****p 0.0001.
Data were analyzed with a two-way ANOVA and a post hoc Tukey test (A–D) or with the comparison of the survival curves with a
Mantel-Cox test (E); n 8.
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resident microglial cells as the major mechanism for population
expansion (Ajami et al., 2007; Mildner et al., 2007, 2011). The
recent studies highlight the need to use noninvasive orminimally
invasive tools to study the recruitment and/or differentiation of
circulating progenitors to the brain. A previous study reported
recruitment of peripheral BMPs in prion disease (Priller et al.,
2006), although the use of irradiation protocols would com-
pound the interpretations about the origin of the microglial
expansion, as the recruitment of BMPs to sites of neurodegenera-
tion is rare in conditions where there is no experimental altera-
tion of the system (Mildner et al., 2011; Prinz andMildner, 2011).
Therefore, we conclude now that local proliferation sustains the
expansion of the microglial population during prion disease.
During prion disease, microglia have a cytokine profile that
resembles that found in models of Alzheimer’s or Parkinson’s
disease, with modest or little contribution of proinflammatory
cytokines to the microglial activated phenotype (Perry et al.,
2007). Recent reports, using ablation of proliferating CD11b
cells, suggest a neutral or benign role of microglia during neuro-
degenerative diseases (Gowing et al., 2008; Grathwohl et al.,
2009). However, alternative approaches are needed to suppress
microglial proliferation, as the transgenic depletion of microglia
in these models could interfere with the normal development of
the disease due to an incomplete depletion (Audet et al., 2012) or
the generation of a response tomassive microglial apoptosis. The
use of nonselective antiproliferative agents, like AraC, arrested
themicroglial expansion but caused a shift to a proinflammatory,
antigen-presenting phenotype as a side effect. In the AraC-
treated ME7 mice, we can observe two microglial phenotypes:
one characterized by high expression of CSFR1 and another, den-
dritic cell-like, with high expression ofMHCII, IL1, andCD11c.
A similar change in response to AraC has been recently described
in a model of amyotrophic lateral sclerosis, supporting our find-
ings and highlighting the negative side effects of AraC in neuro-
degenerative conditions (Audet et al., 2012), correlating with the
observed effect of AraC in accelerating the neurodegeneration.
Alternatively, the use of genetic manipulation of the components
of the CSF1R mitogenic pathway could be of help to study mi-
croglial proliferation in disease. However, the critical role of the
CSF1R-PU.1-C/EBP system for the development of the hema-
topoietic system impacts on the application of knock-out strate-
gies. Mutations in both CSF1R and IL34 do not provide viable
mice, while mutations of CSF1 (op/op mice) results in viable
mice with numerous developmental abnormalities (for review
see Hume and MacDonald, 2012). PU.1/mice do not survive
longer than 20 d, showing multiple hematopoietic abnormalities
(McKercher et al., 1996). C/EBP/mice do not survive longer
than 8 h after birth, due to severe hypoglycemia (Wang et al.,
1995). Targeting the pathways specifically activated in proliferat-
ing microglia provides the opportunity to study the temporal
course of the pathology in the presence of a nearly normal density
of microglia. Using GW2580 to selectively inhibit the CSF1R ty-
rosine kinase activity (Conway et al., 2005), we blocked the ex-
pansion of the microglial population and identified the harmful
contribution of the microglial population to the development of
the disease. We found that treatment with GW2580 over the
course of prion disease led to significant reduction of neuronal
degeneration, reflected in an improvement in the behavioral per-
formance and survival. These results correlate with previous
findings reporting a beneficial effect of GW2580 in the treatment
of an experimental model of multiple sclerosis (Crespo et al.,
2011) and provide a potent tool to target the innate immune
response during chronic neurodegeneration.
We identified the systemofCSF1R and itsmitogens, CSF1 and
IL34, as the main drivers of microglial proliferation during
chronic neurodegeneration. Although this systemwas previously
related to the control of in vivomicroglial proliferation (Kondo et
al., 2007), no previous study reported on these effects during
chronic neurodegeneration. Inhibition of the activity of CSF1R
with a blocking antibody was effective in controlling the expan-
sion of the microglial population, as previously described for
other macrophage populations (MacDonald et al., 2010). The
activation of the cell cycle in microglia is dependent on CSF1R
through the downstream activation of cyclinD (Yamamoto et al.,
2012), a feature also observed in our model. The autocrine pro-
duction of CSF1 has been previously reported to have a role in the
control of microglial proliferation (Raivich et al., 1994;
Yamamoto et al., 2010). However, the present results are the first
evidence of the expression and activity of IL34 in the brain as part
Figure7. Expression of themicroglial proliferation regulatory proteins in variant Creutzfeldt–Jakob disease andAlzheimer disease.A–C, Immunohistochemical analysis of the expression of IL34
(A), PU.1 (B), and C/EBPa (C) in the white and gray matter of the temporal cortex of vCJD and AD brains compared with age-matched controls (CTL; representative images). Quantification data
expressed as mean SEM of the number of IL34 (D), PU.1 (E), or C/EBPa (F) cells per square millimeters. G, H, Immunohistochemical analysis of the expression of Ki67 (marker of
proliferation, G) in microglial cells (Iba1, G) and IL34 (H) in astrocytes (GFAP, H) in the temporal cortex of vCJD brains. A–C, Nuclei are stained with H/E (blue). G, H, Fluorescent sections
evaluatedwith confocalmicroscopy. *p 0.05, **p 0.01, ****p 0.0001, expressed versus the correspondent age-matched control. Datawere analyzedwith a two-way ANOVA and a post hoc
Tukey test (n 9–10). Scale bars: A–C, G, H (in A, G, H), 100m.
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of a glial cross-regulatory system. A recent report suggests that
IL34 can also be present in neurons, at least at the gene expression
level (Wang et al., 2012). Our results suggest a model of micro-
glial proliferation being controlled by the paracrine production
of IL34 coming from astrocytes at early stages of the disease to be
further maintained by the autocrine production of CSF1 in mi-
croglial cells. This bivalent regulation of microglial proliferation
also appears to have a prominent role in human AD and vCJD.
We found increased IL34-expressing astrocytes in the white mat-
ter of the temporal cortex of AD and vCJD brains, suggesting an
IL34-dependent regulation of microglial proliferation in the
white matter, while an autocrine system could be active in the
graymatter. Although these results define new signals andmech-
anisms regulating microglial proliferation, we still need to iden-
tify which stimuli drive the production of IL34 in astrocytes, as
this is likely a key initial step defining the progression of the glial
reaction in neuropathology.
An important finding reported in this work is the role of the
transcription factors PU.1 and C/EBP in the regulation of the
microglial proliferation. Both PU.1 and C/EBP regulate micro-
glial proliferation during the development of prion disease and
appear upregulated in human vCJD and AD, correlating with
previous findings using expression profiling of incipient AD
(Blalock et al., 2004). Little is known about the role of PU.1 in
microglial biology, although some reports highlight the potential
roles of this transcription factor as a regulator of microglial phys-
iology (Walton et al., 2000). PU.1 is amaster regulator ofmyeloid
differentiation and induces the expression of CD45, CD11b, F4/
80, and MHC class II as well as regulating cell proliferation by
upregulating the CSF1R (Celada et al., 1996; Nishiyama et al.,
2004). Moreover, a regulatory network has been recently de-
scribed in microglia, involving the control by miRNA124 of the
activity of C/EBP and its downstream regulator PU.1
(Ponomarev et al., 2011). The temporal dynamics and levels of
expression of PU.1 and C/EBP in prion disease support the
model of a cooperative effect in the control of microglial prolif-
eration (Ponomarev et al., 2011), with PU.1 acting as a final ef-
fector hub, due to the transcriptional control ofC/EBPover thePU.1
promoter(Yeamansetal.,2007;Caietal.,2008).Ourresultssupportthe
key role of PU.1 and C/EBP in controlling the microglial population
expansion and define a useful target for therapeutic interventions con-
trollingmicroglial populationdynamics.
We propose thatmicroglial priming stems from the activation
of the CSF1R. It has been suggested that macrophage inflamma-
tion can be viewed as a state of “CSF1-resistance,” as continued
activation of this mitogenic pathway maintains cells in an M2-
like phenotype (Hamilton, 2008). The M2-like phenotype of
prion-diseased microglia, characterized by high expression of
TGF (Boche et al., 2006) and active proliferation, can be
switched to anM1 phenotype upon systemic stimulation with LPS,
accelerating disease as a consequence of a priming effect (Perry et al.,
2002, 2007). Changes in the local microenvironment, like focal cell
death or peripheral inflammation, can drive a profound change in
the phenotype of these primed microglia, arresting proliferation
through the activation of TLR4 and inhibition of the PU.1-C/EBP
system (Ejarque-Ortiz et al., 2007; Tusell et al., 2009) and generating
a tissue-damaging proinflammatory phenotype. The observed in-
verse correlation of the expression of CSF1R and CD11c supports
the theory of the proliferative and proinflammatory phenotypes in
microglial cells being mutually exclusive, with a prominent role of
the CSF1R-C/EBP-PU.1 system.
To conclude, we describe the temporal and spatial dynamics
of microglial proliferation during chronic neurodegeneration,
with the activation of CSF1R and the transcription factors PU.1
andC/EBP as the key actors of the regulatory network.We show
that microglia proliferation is driven by CSF1 and IL34 and dem-
onstrated that arresting microglial proliferation during neurode-
generation significantly delays progression of the disease,
indicating an overall harmful contribution by themicroglial cells,
and a route to further delaying disease progression.
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